Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-01
2009-06-16
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C548S518000
Reexamination Certificate
active
07547724
ABSTRACT:
Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I:or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
REFERENCES:
patent: 6110691 (2000-08-01), Wang et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 6992063 (2006-01-01), Shi
patent: 7041784 (2006-05-01), Wang et al.
patent: 7094758 (2006-08-01), Wang et al.
patent: 7229617 (2007-06-01), Nasoff et al.
patent: 7244851 (2007-07-01), Cohen et al.
patent: 7309792 (2007-12-01), Harran et al.
patent: 2004/0180828 (2004-09-01), Shi et al.
patent: 2005/0197403 (2005-09-01), Harran et al.
patent: 2006/0014700 (2006-01-01), Cohen et al.
patent: 2006/0025347 (2006-02-01), Condon et al.
patent: 2006/0194741 (2006-08-01), Condon et al.
patent: 2006/0211627 (2006-09-01), Reed et al.
patent: 2006/0258581 (2006-11-01), Reed et al.
patent: 2007/0032437 (2007-02-01), Shi et al.
patent: 2007/0093428 (2007-04-01), Laurent
patent: 2007/0093429 (2007-04-01), Laurent et al.
patent: 2007/0219140 (2007-09-01), Laurent et al.
patent: 2008/0069812 (2008-03-01), Boudreault et al.
patent: 2008/0089896 (2008-04-01), Wang et al.
patent: 2008/0207525 (2008-08-01), Boudreault et al.
patent: 2 560 162 (2005-10-01), None
patent: 2 574 040 (2006-02-01), None
patent: 61183297 (1986-08-01), None
patent: 04208299 (1992-07-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2005/069888 (2005-08-01), None
patent: WO 2005/084317 (2005-09-01), None
patent: WO 2005/094818 (2005-10-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/069063 (2005-12-01), None
patent: WO 2006/010118 (2006-01-01), None
patent: WO 2006/017295 (2006-02-01), None
patent: WO 2006/069063 (2006-06-01), None
patent: WO 2006/113376 (2006-10-01), None
patent: WO 2006/122408 (2006-11-01), None
patent: WO 2006/128455 (2006-12-01), None
patent: WO 2006/133147 (2006-12-01), None
patent: WO 2007/048224 (2007-05-01), None
patent: WO 2007/075525 (2007-07-01), None
patent: WO 2007/101347 (2007-09-01), None
patent: WO 2007/104162 (2007-09-01), None
patent: WO 2007/106192 (2007-09-01), None
patent: WO 2007/131366 (2007-11-01), None
patent: WO 2007/136921 (2007-11-01), None
patent: WO 2008/014229 (2008-01-01), None
patent: WO 2008/014236 (2008-01-01), None
patent: WO 2008/014238 (2008-01-01), None
patent: WO 2008/014240 (2008-01-01), None
patent: WO 2008/014252 (2008-01-01), None
patent: WO 2008/014263 (2008-01-01), None
patent: WO 2008/016893 (2008-02-01), None
patent: WO 2008/045905 (2008-04-01), None
patent: WO 2008/057172 (2008-05-01), None
patent: WO 2008/067280 (2008-06-01), None
patent: WO 2008/073306 (2008-06-01), None
patent: WO 2008/079735 (2008-07-01), None
patent: WO 2008/085610 (2008-07-01), None
Structure-Based Design, Synthesis and Evaluation of Conformationally constrained mimetics of the second mitochondria-derived activator of caspase (Smac) that target the X-linked inhibitor of apoptosis protein/caspase-9 Interation site; Sun et al.; J. Med. Chem. 2004, 47, 4147-4150.
Structure-Based Design, Synthesis and Evaluation of Conformationally constrained mimetics of the second mitochondria-derived activator of caspase (Smac) that target the X-linked inhibitor of apoptosis protein/caspase-9 Interaction site; Sun et al.; JM0499108, Supporting Information.
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer; Oost et al; Journal of Medicinal Chemistry; pp. A-J; Feb. 13, 2004.
Discovery of potent antagonists of the anti-apoptotic protein XIAP for the treatment of cancer; Oost et al; 2004 American Chemical Society, J. Med. Chem.; Supporting Information.
A small molecule smac mimic potentiates TRAIL—and TNFα-Mediated Cell death; Li et al.; Science vol. 305; Sep. 3, 2004; 1471-1474.
A small molecule smac mimic potentiates TRAIL—and TNFα-Mediated Cell death; Li et al.; Supporting information.
Non-peptidic small molecule inhibitors of XIAP; Park et al.; Bioorganic & Medicinal Chemistry Letters 15 (2005) 771-775.
Discovery of embelin as a Cell-Permeable, Small-Molecular Weight Inhibitor of XIAP through Structure-Based Computational Screening of a Traditional Herbal Medicine Three-Dimensional structure Database; Nikolovska-Coleska et al.; J. Med. Chem. 2004, 47, 2430-2440.
Structure-based design, synthesis and biochemical testing of novel and potent Smac peptide-mimetics; Sun et al.; Bioorganic & Medicinal Chemistry Letters 15 (2005) 793-797.
Design and synthesis of a potent biotinylated Smac mimetic; Sun et al.; Tetrahedron Letters 46 (2005) 7015-7018.
Development and Characterization of Nonpeptidic Small Molecule Inhibitors of the XIAP/Caspase-3 Interaction; Wu et al.; Chemistry & Biology, vol. 10, 759-767, Aug. 2003.
Design, Synthesis, and Biological Activity of a potent Smac Mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs; Zobel et al.; ACS Chemical Biology; vol. 1 No. 8, 2006; 525-533.
Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein; Chen et al.; Bioorganic & Medicinal Chemistry Letters (2006); doi:10.1016.
Arnt et al.,J. Biol. Chem., “Synthetic Smac/Diablo peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in Situ,” 277(46): 44236-44243 (2002).
Bertrand et al.,Mol. Cell, “cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination,” 30: 689-700 (2008).
Bucher et al.,Helv. Chim. Acta., 78(4):935-46 (1995).
Chai et al.,Nature, “Structural and biochemical basis of apoptotic activation by Smac/Diablo,” 406: 855-62 (2000).
Chauhan et al.,Blood, “Targeting mitochondrial factor Smac/Diablo as therapy for multiple myeloma (MM),” 109(3): 1220-7 (2007).
Eckelman et al.,Cell Death Differ., “The mechanism of peptide-binding specificity of IAP BIR domains,” 15(5): 920-8 (2008).
Elmore et al.,Annual Rep. Med. Chem., “Inhibitors of Anti-apoptotic Proteins for Cancer Therapy,” 40: 245-62 (2006).
Franklin et al.,Biochemistry, “Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP),” 42: 8223-31 (2003).
Fulda et al.,Nature Medicine, “Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo,” 8: 808-15 (2002).
Gao et al.,J. Biol. Chem., “A dimeric Smac/Diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo,” 282(42): 30718-27 (2007).
Haining et al.,Proc. Natl. Acad. Sci. USA, “The proapoptotic function ofDrosophilaHID is conserved in mammalian cells,” 96(9): 4936-41 (1999).
Kipp et al.,Biochemistry, “Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners,” 41: 7344-9 (2002).
Liu et al.,Nature, “Structural basis for binding of Smac/Diablo to the XIAP BIR3 domain,” 408: 1004-8 (2000).
Marik et al.,J. Peptide. Res., “Synthesis and effect of shortened oostatic decapeptide (TMOF) analogs with isosteric structures on reproduction ofNeobellieria bullata,” 57(5): 401-8 (2001).
McCarthy et al.,J. Biol. Chem., “Apoptosis induced byDrosophilareaper and grim in a human system. Attenuation by inhibitor of apoptosis proteins (cIAPs),” 273(37): 24009-15 (1998).
Nikolovska-Coleska et al.,Anal. Biochem., “Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization,” 332: 261-273 (2004).
Nikolovska-Coleska et al.,Anal. Biochem., “Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 do
Boudreault Alain
Bureau Patrick
Hewitt Kim E.
Jaquith James
Jarvis Scott
Aegera Therpeutics, Inc.
Coppins Janet L
Leydig , Voit & Mayer, Ltd.
Shiao Rei-Tsang
LandOfFree
IAP BIR domain binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IAP BIR domain binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IAP BIR domain binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142748